(Reuters) – Medtronic Plc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration highlighting certain concerns related to medical device quality requirements at the company’s diabetes business headquarters.
(Reporting by Amruta Khandekar; Editing by Krishna Chandra Eluri)
